<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01760941</url>
  </required_header>
  <id_info>
    <org_study_id>MCC-14596</org_study_id>
    <secondary_id>NCI-2012-03117</secondary_id>
    <nct_id>NCT01760941</nct_id>
  </id_info>
  <brief_title>Compassionate Same-Day Evaluation &amp; Delivery of XRT for Bony Metastasis in Hospice Patients</brief_title>
  <official_title>Feasibility of a Compassionate Same-Day Evaluation and Delivery of Single Fraction Radiotherapy for Palliation of Symptomatic Bony Metastasis in Hospice Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a survey study to evaluate the feasibility and effectiveness of an affordable, $400
      flat rate, same-day consultation, simulation, and delivery of a single fraction of palliative
      radiation therapy for patients with symptomatic bony metastatic disease who are currently
      enrolled in hospice. Treatment planning and delivery of palliative radiotherapy will utilize
      &quot;standard of care&quot; techniques.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date>March 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility of Treatment Delivery in the Same Day as Initial Evaluation</measure>
    <time_frame>Up to 6 months</time_frame>
    <description>Patient evaluation will consist of surveys conducted at the time of treatment measured by the Radiation Oncologist Evaluation and Feasibility Assessments survey</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Treatment Influence on the Rate of Pain Stabilization and/or Reduction</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluate the treatment influence on the rate of pain stabilization and/or reduction as measured by the validated BPI patient questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate the Treatment Influence on Patient Quality of Life</measure>
    <time_frame>2 weeks</time_frame>
    <description>Evaluate the treatment influence on patient quality of life as measured by the ESAS.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Quantify the Percentage of Patients Receiving the Treatment Who Believe That the Treatment Was Worthwhile</measure>
    <time_frame>6 months</time_frame>
    <description>Quantify the percentage of patients receiving the treatment who believe that the treatment was worthwhile</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Symptomatic Osseous Bone Lesions From Any Malignancy</condition>
  <arm_group>
    <arm_group_label>Treatment (radiation therapy)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This is a survey study to evaluate the feasibility and effectiveness of an affordable, $400 flat rate, same-day consultation, simulation, and delivery of a single fraction of palliative radiation therapy for patients with symptomatic bony metastatic disease who are currently enrolled in hospice. Treatment planning and delivery of palliative radiotherapy will utilize &quot;standard of care&quot; techniques. A physician survey of feasibility will be conducted on the treatment day. Patient surveys will conducted on the day of treatment and at 2 weeks, 4 weeks, 2 months, 3 months, 4 months, 5 months, and 6 months after treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation Therapy</intervention_name>
    <description>Undergo standard of care radiation therapy</description>
    <arm_group_label>Treatment (radiation therapy)</arm_group_label>
    <other_name>RT</other_name>
    <other_name>Irradiation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.</description>
    <arm_group_label>Treatment (radiation therapy)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Survey Administration</intervention_name>
    <description>The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.</description>
    <arm_group_label>Treatment (radiation therapy)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Symptomatic osseous bone lesion(s) from any malignancy, whether primary of metastatic,
             with histological confirmation of malignancy.

          -  Currently enrolled in hospice and referred for single fraction palliative
             radiotherapy.

          -  Performance status (to be evaluated by the radiation oncologist), Karnofsky
             Performance Scale ≥ 20 or ECOG Performance Scale &lt; 5 .

          -  Ability to understand and willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Pregnancy.

          -  Unable to understand English.

          -  Unable to complete forms with assistance.

          -  Concurrent enrollment in a study of pain management involving medications or devices.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Drew Moghanaki, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Virginia Commonwealth University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia Commonwealth University/Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2012</study_first_submitted>
  <study_first_submitted_qc>January 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 4, 2013</study_first_posted>
  <results_first_submitted>December 18, 2015</results_first_submitted>
  <results_first_submitted_qc>January 29, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 29, 2016</results_first_posted>
  <last_update_submitted>January 29, 2016</last_update_submitted>
  <last_update_submitted_qc>January 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 29, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Urology</keyword>
  <keyword>Prostate</keyword>
  <keyword>Breast</keyword>
  <keyword>Lung</keyword>
  <keyword>Chest</keyword>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Radiotherapy</title>
          <description>Single fraction radiotherapy
Radiotherapy: Single fraction radiotherapy. All study participants will be evaluated, simulated, and treated with conventional single fraction palliative radiotherapy using standard techniques with CT-based treatment.
planning.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Radiotherapy</title>
          <description>Single fraction radiotherapy
Radiotherapy: Single fraction radiotherapy. All study participants will be evaluated, simulated, and treated with conventional single fraction palliative radiotherapy using standard techniques with CT-based treatment.
planning.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility of Treatment Delivery in the Same Day as Initial Evaluation</title>
        <description>Patient evaluation will consist of surveys conducted at the time of treatment measured by the Radiation Oncologist Evaluation and Feasibility Assessments survey</description>
        <time_frame>Up to 6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Radiotherapy</title>
            <description>Single fraction radiotherapy
Radiotherapy: Single fraction radiotherapy. All study participants will be evaluated, simulated, and treated with conventional single fraction palliative radiotherapy using standard techniques with CT-based treatment.
planning.</description>
          </group>
        </group_list>
        <measure>
          <title>Feasibility of Treatment Delivery in the Same Day as Initial Evaluation</title>
          <description>Patient evaluation will consist of surveys conducted at the time of treatment measured by the Radiation Oncologist Evaluation and Feasibility Assessments survey</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Treatment Influence on the Rate of Pain Stabilization and/or Reduction</title>
        <description>Evaluate the treatment influence on the rate of pain stabilization and/or reduction as measured by the validated BPI patient questionnaire.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Radiotherapy</title>
            <description>Single fraction radiotherapy
Radiotherapy: Single fraction radiotherapy. All study participants will be evaluated, simulated, and treated with conventional single fraction palliative radiotherapy using standard techniques with CT-based treatment.
planning.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Treatment Influence on the Rate of Pain Stabilization and/or Reduction</title>
          <description>Evaluate the treatment influence on the rate of pain stabilization and/or reduction as measured by the validated BPI patient questionnaire.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Evaluate the Treatment Influence on Patient Quality of Life</title>
        <description>Evaluate the treatment influence on patient quality of life as measured by the ESAS.</description>
        <time_frame>2 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Radiotherapy</title>
            <description>Single fraction radiotherapy
Radiotherapy: Single fraction radiotherapy. All study participants will be evaluated, simulated, and treated with conventional single fraction palliative radiotherapy using standard techniques with CT-based treatment.
planning.</description>
          </group>
        </group_list>
        <measure>
          <title>Evaluate the Treatment Influence on Patient Quality of Life</title>
          <description>Evaluate the treatment influence on patient quality of life as measured by the ESAS.</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Quantify the Percentage of Patients Receiving the Treatment Who Believe That the Treatment Was Worthwhile</title>
        <description>Quantify the percentage of patients receiving the treatment who believe that the treatment was worthwhile</description>
        <time_frame>6 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Radiotherapy</title>
            <description>Single fraction radiotherapy
Radiotherapy: Single fraction radiotherapy. All study participants will be evaluated, simulated, and treated with conventional single fraction palliative radiotherapy using standard techniques with CT-based treatment.
planning.</description>
          </group>
        </group_list>
        <measure>
          <title>Quantify the Percentage of Patients Receiving the Treatment Who Believe That the Treatment Was Worthwhile</title>
          <description>Quantify the percentage of patients receiving the treatment who believe that the treatment was worthwhile</description>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>As this is a survey study and not a drug study, changed from an “Adverse Events” section to a “Study Risks” section. No AEs or SAEs were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>Radiotherapy</title>
          <description>Single fraction radiotherapy
Radiotherapy: Single fraction radiotherapy. All study participants will be evaluated, simulated, and treated with conventional single fraction palliative radiotherapy using standard techniques with CT-based treatment.
planning.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="0"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No data analysis or outcome measures for one participant enrolled and zero participants analyzed. Early suspension and termination due to slow accrual from Protocol Review and Monitoring Committee.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Drew Moghanaki, MD, MPH</name_or_title>
      <organization>Virginia Commonwealth University/Massey Cancer Center</organization>
      <phone>804-765-5850</phone>
      <email>Drew.moghanaki@vcuhealth.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

